ArticleAdvances in therapy2022

Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand.

Kriengsak Vareesangthip et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.